Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
BACKGROUND
Pathogen reduction technologies (PRTs) increase the safety of the blood supply, but are also associated with cell damage. Our aim was to investigate the effect of Mirasol PRT on platelet (PLT) concentrates stored in plasma and whether the use of a PLT additive solution (PAS) is able to improve in vitro quality.


METHODS
Twenty-two buffy coats (BCs) were pooled and split into two equal parts. To one half, 2 units of plasma were added, and to the other, 2 units of SSP+ PAS were added. Each part was equally split in half again (to resemble pooling five BCs) and PLT concentrates were prepared. One plasma PLT concentrate was Mirasol treated, and the other served as control; similarly, one SSP+ PLT concentrate was Mirasol treated, and the other not. PLT concentrates were stored for 8 days (n = 12).


RESULTS
Mirasol PRT led to elevated lactate production in PLT concentrates in plasma, giving lower pH values throughout storage. The use of SSP+ mostly abrogated this effect, and Mirasol-treated PLT concentrates in SSP+ had only slightly higher lactate production rates and annexin A5 binding as control PLT concentrates in plasma. However, irrespective whether plasma or SSP+ was used, Mirasol PRT led to higher CD62P expression and lower hypotonic shock response (HSR) scores.


CONCLUSIONS
Mirasol treatment leads to higher PLT activation and lower HSR scores both when stored in plasma or SSP+. However, if Mirasol-treated PLTs are stored in SSP+, lactate metabolism and annexin A5 binding are lower, showing that PAS can partly mitigate the effect of PRT. The clinical relevance of this finding needs to be demonstrated.
Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, the Netherlands.
Pieter F
PF
van der Meer
Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, the Netherlands.
Ido J
IJ
Bontekoe
Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, the Netherlands.
Brunette B
BB
Daal
Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, the Netherlands.
Dirk
D
de Korte
D017304:Annexin A5 / Q000378:metabolism; D001639:Bicarbonates / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects* / Q000528:radiation effects; D001793:Blood Preservation; D058731:Blood Safety / Q000379:methods*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007038:Hypotonic Solutions / Q000494:pharmacology; D007773:Lactates / Q000097:blood; D009997:Osmotic Pressure; D019007:P-Selectin / Q000032:analysis; D010710:Phosphates / Q000097:blood; D010949:Plasma; D015539:Platelet Activation / Q000187:drug effects*; D012256:Riboflavin / Q000494:pharmacology*; D012996:Solutions; D014466:Ultraviolet Rays
D017304:Annexin A5; D001639:Bicarbonates; D001786:Blood Glucose; D007038:Hypotonic Solutions; D007773:Lactates; D019007:P-Selectin; D010710:Phosphates; C546937:SELP protein, human; D012996:Solutions; D012256:Riboflavin